key: cord-0862595-cl8c8nuh
authors: Cozzolino, Mario; Conte, Ferruccio; Zappulo, Fulvia; Ciceri, Paola; Galassi, Andrea; Capelli, Irene; Magnoni, Giacomo; La Manna, Gaetano
title: Covid-19 Pandemic Era: Is It Time To Promote Home Dialysis And Peritoneal Dialysis?
date: 2021-02-02
journal: Clin Kidney J
DOI: 10.1093/ckj/sfab023
sha: a07ae7a2974983a0e7431239a71ca3f2fcc2cc37
doc_id: 862595
cord_uid: cl8c8nuh

The novel coronavirus, called SARS-CoV-2 has been declared a pandemic on March 2020, by the World Health Organization. Older individuals and patients with comorbid conditions such as hypertension, heart disease, diabetes, lung disease, chronic kidney disease (CKD), and immunologic diseases are at higher risk of contracting this severe infection. In particular, patients with advanced CKD constitute a vulnerable population and a challenge in the prevention and control of the disease. Home-based renal replacement therapies offer opportunity to manage patients remotely, thus reducing the likelihood of infection due to direct human interaction. Patients are seen less frequently, limiting the close interaction between patients and healthcare workers who may contract and spread the disease. On the other hand, while home dialysis is reasonable selection at his time due to the advantage of isolation of patients, measures must be assured to implement the program. Despite its logistical benefits, outpatient hemodialysis also presents certain challenges during times of crises such as COVID 19 pandemic and potentially future ones.

SARS-CoV-2, the virus responsible for COVID-19 pandemic, caused till now more than 35million cases and more than one million deaths in 235 countries around the world, according data from WHO [1] . Its spread has affected the general population with symptoms often similar to those of a common first airway infection, while in fewer instances it has led to a severe respiratory syndrome with high fever, bilateral interstitial pneumonia, often requiring hospitalization in intensive care wards and followed by an adverse outcome [2] . Infection fatality rate in general population has been estimated ranging from 0.5% to 1% [3], but there is a great variability among countries and clusters of population. Infectivity of the virus is high, it occurs by aerosols through the spread of droplets released by infected people, by coughing, sneezing and even talking in close contact, even if there are no clear symptoms. The disease has a more severe manifestation in some subjects in relation to older age and the presence of comorbid diseases [4] (Table 1) . This is especially evident in patients with CKD and more dramatically in those undergoing haemodialysis treatment. The spread of the pandemic of novel coronavirus disease COVID-19 have highlighted the importance of limiting social activities in order to decrease the risk of exposure to SARS-CoV-2. Dialysis patients are considered to be at higher risk of developing severe COVID-19 because of their immunocompromised status and the underlying medical condition. Home-based renal replacement therapies have many advantages in this regard.

CKD patients are particularly vulnerable to respiratory diseases due to a functionally inadequate immune system [5] and to the need for frequent hospital admissions. The dysfunction of the immune system in uremic patients is related to alterations in both the innate and adaptive immunity systems. These two alterations, associated with the 3 presence of uremic toxins, nutritional deficiencies and immunosuppressive therapies, make infectious diseases the second leading cause of death in CKD patients, after cardiovascular disease. This impairment results in an increased susceptibility to bacterial and viral infections, poor vaccination responses and increased risk of malignancies. These changes in immune system might resemble premature immunological ageing and might reflect an alteration in the lymphoid and myeloid hematopoietic stem cell ratio [6] . In a recent survey [7] , conducted by the Italian Society of Nephrology on the risks of infection by SARS-CoV-2 of CKD patients undergoing renal replacement therapy during the exponential growth phase of the pandemic in the country, it was found that, during the surveyed period, 1368/60441 patients (2.26%) had contracted SARS-Co V-2 infection, while the percentage of infection in the general population was estimated to be around 0.4% [8] . A second important risk factor for SARS-CoV-2 infection in dialysis patients can be related to organisation of hospital facilities in providing dialysis treatment.

Replacement dialysis treatment can be performed using three main modalities: haemodialysis, peritoneal (PD) dialysis and transplantation. In the previously mentioned survey of the Italian Nephrology Society out of 60441 patients on renal replacement therapy ( RRT), 51% were on haemodialysis, 7% on PD and 42% on transplantation. In the United States Renal Data System (USRDS) registry relating to the year 2017, haemodialysis patients accounted for 62.9%, PD patients for 7.1% and transplant patients for 30% [9] . Worldwide, 89% of dialysis patients living in high-medium income countries, are on a haemodialysis treatment, and the use of this modality of RRT is growing faster in Latin American countries than in Europe and the United States [10] . Thus the dialysis treatment in most developed countries is carried out almost exclusively by haemodialysis in hospital or limited care Units, at by three sessions a week, with an average duration of 4 hours each. This dialysis schedule inevitably leads, given the increasing number of patients, to setting up dialysis rooms with more and more patients and consequently more crowded. Often the dialysis room is full with so many dialysis beds that it is not possible to maintain an adequate safety distance between patients. In addition, haemodialysis patients are transported to the hospital dialysis Units from their homes in groups, almost never individually, and are waiting for the start of the haemodialysis treatment in a waitingroom that, due to spatial problems, often is not able to ensure adequate distance, and 4 sometimes a proper air renewal . In such a scenario of a pandemic with high diffusivity, it is clear that patients in hospital haemodialysis may be more prone to be infected than the general population with comparable comorbidities and age. From this, under the pressure of the pandemic, in order to reduce the risk of infection by SARS-CoV-2 in dialysis patients, it seems crucial to explore new management modalities. There may be other options than intra-hospital dialysis performed with a three-weekly treatment schedule of 4 hours, although so far they have not had extensive application. Home haemodialysis (HHD), incremental haemodialysis, nocturnal haemodialysis, PD may be treatment modalities well known, well-structured and already used for a long time with alternating successes. [11] . Their use differs widely: with regard to extra-hospital techniques, it ranges from a minimum of 3% in Japan to 28% in New Zealand, reaching 46% in Hong Kong.

The rise of HHD developed already in the 60's and 70's in the USA and the UK under the pressure of the need to provide dialysis treatment to an increasing number of patients in the face of a shortage of intra-hospital dialysis workstations [12] . In the early 1970s, in fact, 59% of patients in the UK and 32% in the USA were performing haemodialysis at home, especially overnight [13] . In the last 50 years, there has been a huge growth in the number of patients with End Stage Renal Disease (ESRD) worldwide, with a corresponding exponential growth in the number of dialysis patients. Despite this exponential growth of the total number of dialysis patients, the percentage of those in HD at home since the 1970s has decreased and remains surprisingly low [12] , while the number of patients dialyzed in hospital and satellite Units has increased significantly. It is quite complex to get an accurate information about the number of dialysis patients hometreated in the world. Not all dialysis registries collect this data, and in addition there is a significant difference between the number of patients starting an HHD program and those who are continuing for a substantial period of time. According to a historical paper (2006) the prevalence of haemodialysis at home showed a wide variability between the various countries, ranging from a high use in Australia and New Zealand (39 and 58.4% respectively) to a much lower one in the United States (4.6%) and in other European countries (Scotland and Holland 8.6% and 6.2%) [14] . More recent data show a further reduction in the percentage of HHD in Europe with a percentage <2%, and only slightly 5 higher (4%) in the UK [15] . Currently, data referring to Italy show a prevalence of HHD of 1.08% on a total of 46000 patients in hospital or limited care haemodialysis [16] . This underutilization of HHD seems in contrast to the several benefits that, even in no-Covid times, are widely described in the literature [17] . HHD is in fact able to provide maximum flexibility in treatment schedules to customize the dialysis treatment by modifying blood flow and dialysate, treatment duration and frequency. This flexibility can also be adapted to the patient's needs in order to leave as much time of the day available to the patient's activities by varying the timetables (night/day and so on). The clinical benefits of HHD are manifested in both improved survival and reduced morbidity compared to three-weekly in dialysis Units [18] [19] . The HHD allows patients a more physiological treatment scheme as it can be performed daily or at least avoiding the long inter-dialytic gap, reducing cardiovascular stress by a lower ultrafiltration rate. It is well known, in fact, that high ultrafiltration rates during treatment are an important cardiac risk factor [20] [21] . In addition to the advantages related to a reduction of left ventricular hypertrophy, an appropriate HHD schedule allows better management of blood pressure and phosphate control with a reduction of drugs in both instances [22] [23] . Also from an economic point of view, both nocturnal and daily HHD have proven to be cost-effective compared to intra-hospital dialysis [24] [25] .

In the clinical practice mainly adopted so far in Western countries, the choice to encourage patients to adhere to a HHD treatment program has encountered several obstacles, partly patient dependent, partly nephrologist dependent. On the patient's side there may be no willingness to adhere for fear of making mistakes, fear of not having an adequate treatment equal to that provided in hospital dialysis, fear of being left alone to manage their life-saving treatment, fear of needle puncture etc [26] . In addition, nephrologists themselves are not enough convinced of the usefulness of the procedure so that it is not even proposed to the patient or implemented among the dialysis modalities. The possibility to perform HHD should be discussed with all CKD stages 4-5 patients, trying to promote independence and autonomy, to improve quality of life, and to obtain clinical benefits.

Clearly, the counselling process prior to dialysis initiation appears to be in favour to the choice of HHD over conventional in-centre dialysis and pre-ESRD educational intervention has been proved to be the best contributor to orientation toward HHD [27, 28] . 6 Furthermore, often a high percentage of patients are taken care of by the nephrologist too late, just a few weeks before they have to start dialysis [29] . So starting haemodialysis in hospital as a late referral, these patients are not aware of the possibility of HHD treatment.

It would be advisable that all patients with ESRD are properly educated on the choice of method when their Glomerular Filtration Rate (GFR) is far enough away from the need of beginning of the replacement therapy, although a well-structured educational program can begin also after an urgent-start dialysis, with good results of a transition to home modality [30] . Appropriate identification of suitable patients should be a priority for dialysis Units in order to refer as many patients as possible to a home treatment. Some years ago the International Society of Haemodialysis (ISHD) published with the contribution of nephrologists and nurses experienced in the management of home dialysis programs a comprehensive manual [31] that should provide adequate support and knowledge in order to expand the home program, useful for those nephrologists not trained in home dialysis.

The recent initiative called "Advancing American Kidney Health" designed to reduce risk of kidney failure, has three important goals, one of which is to send 80% of new patients with ESRD to home dialysis or transplant for 2025, with the aim, if successful, to transform the lives of CKD patients in the U S and change most of the clinical practice of nephrology [32] . To date, in the presence of the COVID-19 pandemic, specific data on the epidemiology and clinical picture of the infection in patients on HHD are still not well defined. However, it is reasonable to assume that, since there are no substantial differences in comorbidities, immunocompromised state and metabolic alterations, the theoretical susceptibility to COVID-19 does not differ between patients in haemodialysis Units and those at home. The theoretical advantage of home dialysis patients is to perform dialysis treatment at home without the need to move to the hospital setting, reducing the possibility of exposure to the risk of infection. While benefiting from this undoubted advantage, patients on HHD, in a period of pandemic may suffer from forced isolation, from problems in the supply of dialysis products, from difficulty in carrying out blood tests, from ability to have direct contact with health care staff [33] . The possible expansion of the use of HHD in the COVID-19 era will have an impact on the organization of dialysis Units.

Our experience, gained during the COVID-19 pandemic, offers the opportunity to modify the current dialysis care system through a new approach oriented to the clinical and social priorities of the patient. HHD could be a tool to improve patient outcomes, developing new procedures under the umbrella of local and national rules, in which macroeconomic and regulatory innovations should be made by central decision makers [34] .

The manufacturing companies should receive input for the development and research of materials and devices more biocompatible and efficient, easiest to manage at patient home, with bidirectional communication capabilities with the dialysis units. Educational programs should be activated early in the advanced stages of the disease. These should accomplish a knowledge and familiarization with all the available treatment modalities, presenting the intrinsic pros and cons, providing patients with the theoretical and practical tools to overcome possible difficulties. This educational activity can only be managed by trained and committed medical and nursing staff, who are very confident in these proposed choices. One factor that may explain the under use of educational benefits is that nephrologists do not receive extensive training in HHD. In fact, it has been shown that approximately 15% of nephrologists felt confident in their approach to HHD patients, and those who feel confident in HHD tend to prescribe it to a greater extent [35] . The use of bidirectional communication technologies operating in real time would allow many goals: i) limit to the lowest possible extent the patient's fear of treatment responsibility (the selfpuncturing problem for instance); ii) the coming of patients to the hospital; iii) the patient's clinical condition; iv) and at the same time an accurate control of patient compliance.

Telehealth and telemedicine systems must be integrated with equipment software, which must have a simple and intuitive patient interface. During the COVID-19 pandemic in the New York City, it was possible for a care provider to offer the possibility to perform monthly visits to 150 patients on PD and 60 on HHD by remote, through systems integrated with the software of the PD and HD machines. [36] . The experiences intervened by necessity due to COVID-19 pandemic, should stimulate to new perspectives to implement the best treatment for each patient with ESRD. Telehealth and tele-monitoring procedures are necessary to ensure treatment safety by expanding the range of treatments to as many patients as possible.

Furthermore, dialysis costs are high and likely are continuing to rise due to increased life expectancy and morbidities in ESRD. RRT accounts for 5 -7% of the total health care budgets, despite affected patients only representing 0.1-0.2% of the general population [37] . HHD treatments (HD and PD) have economic advantages over in-hospital dialysis, but despite this, except in countries such as Hong Kong and Thailand where the choice of treatment is not free, their use is marginal (Fig. 2) , likely due to the presence of barriers 8 and conflicting opinions among practitioners and policy makers [38] . At this regard, it is not possible to produce a universal paradigm, given that from an economic perspective itself, conditions may vary greatly between different Countries. In this regard data from the Australian dialysis registry show a 38% difference in treatment costs between in-hospital haemodialysis and HHD with the cost of peritoneal dialysis very similar to the latter [39] .

For better HHD outcomes and patient acceptance remote counselling should be organized with dedicated staff able to ensure the widest possible temporal coverage, enhancing the patient's life choices. The use of the latest generation of dialysis machines can allow the monitoring of dialysis adequacy and minimize the need for blood tests that could be performed at the patient's home [11, 33] . Precise pathways for the treatment of urgencies Although considerable progress has been made in recent years in the treatment of uremic patients, survival data cannot yet be considered optimal. The periodicity of volume and metabolic control are likely to be improved. Home dialysis treatment allows flexibility to achieve optimal purification without increasing costs. With regard to the current COVID-19 pandemic scenario, home treatment adds an additional benefit by reducing the risk of virus exposure and infection. The increase in home treatments also allows a reduction in hospital dialysis crowding and also increases the ability not to exclude any patient from treatment. Haemodialysis home treatment reduces the need for three-weekly trips home to the hospital dialysis Units and back to which may constitute another risk of infection, thus also saving money and reducing polluting emissions. However, in order to achieve an increase in the use of home care dialysis techniques, several conditions are also needed, such as the availability of user-friendly dialysis equipment, telematics monitoring and counselling assistance by telehealth systems, reorganization of dialysis Units and retraining of dedicated staff providing a systematic approach to the problem with the supply of adequate incentives for doctors and patients to choose a home care treatment [40] . The 9 shift of dialysis treatment modalities towards home dialysis are certainly not quick to perform, and need first of all a change of thinking in the nephrologists, in the administrators and lastly in the patients themselves. The COVID-19 pandemic has dramatically highlighted the inadequacy of the current health care organization in the control of infectious risk in highly sensitive populations due to the need for frequent attendance for treatment in hospital wards.

The "stay-at-home" messages given during the pandemic can increase the choice to provide RRT through PD. In fact, PD offers the opportunity to manage patients remotely, thus reducing contagion during an epidemic [41] . The clear goal is to break the chain of transmission through the dialysis unit. Compared to in dialysis Units, PD can be easily performed by patients themselves at home. Physicians can conduct telemedicine consultations and PD prescriptions. In addition to the need for high volumes of clean dialysate, machines, circuits and spaces, in dialysis Units requires a large number of healthcare workers such as physicians, nurses, technicians and janitors. However, the number of such healthcare workers may be reduced due to illness or quarantine. In the era of the COVID-19 pandemic, maintaining adequate dialysis workforce is challenging. It's worth to reduce the patient's chances of getting into contact with other people or going to healthcare facilities, thereby minimizing the risk of SARS-CoV-2 infection.

Previously, during 2009 Pandemic H1N1 Influenza, it has been already demonstrated that the risk of infection in dialysis patients was lower among PD patients. This finding suggests the possibility of differential influenza susceptibility by dialysis modality, suggesting a previously unidentified risk factor for influenza incidence [42] . and consultations should otherwise be conducted by telehealth [43] . In the United Kingdom, by April 29, 2020, 2.9% of patients on PD were reported to have contracted COVID-19 compared with 9% of patients on haemodialysis [44] . 10 The survey of the Italian Society of Nephrology regarding the exposure to novel coronavirus in patients on renal replacement therapy published on June 2020 reported a lower incidence of COVID-19 in PD patients compared to HD (1.38% vs 3.55%) but an higher fatality rate comparing to HD (45% vs 33.76%) [7] .

A study on 818 patient on maintenance PD in Wuhan population showed that only 8 patients were diagnosed with COVID-19 during the pandemic period and the incidence of symptomatic SARS-CoV-2 infection was 2.44 per 1000 person-months in general population. At presentation PD patients present classical symptoms, radiological features and laboratory findings as the general population. According to their findings the incidence of symptomatic COVID-19 in patients on PD was close to that of the general population indicating that the PD population was not a high risk population for COVID-19 [45] . Similarly Ronco et al described the incidence of SARS-CoV-2 pneumonia in dialysis population of Veneto region and Vicenza Area in Italy during the pandemic period: they demonstrated that, comparing to HD, PD allowed to have a significantly lower rate of COVID-19 (ratio 1:3). Moreover they found a significant lower rate of all cause hospitalization (2:5 patients/month) in PD patients compared to HD patients. None of PD patients was admitted to hospital for COVID-19 symptoms. Compared to the same period of the previous year, the number of hospital visits was reduced and the incidence of peritonitis episodes was low (maintained below 0.2/patient/year). The rate of hospitalization for causes independent from PD treatment was 2 patients/month with a reduction of 76% compared to the same months of the previous year. They also reported a significant hospital access restriction for cases that could be deferred (elective surgery, diagnostic procedures). Nonetheless patients are reporting a sense of attention and care to their problems and there was no complaints for lack of care or lack of attention to specific problems [46] . Alfano and Mussini present a different PD perspective during the COVID-19 pandemic, endorsing PD as the preferred RRT modality for ESRD patients. Among the advantages, they mention the minimized risk of viral transmission through interpersonal contacts, as well as the use of telemedicine to deliver renal care without exposure of the patient to the risks of contacts [47] .

PD in COVID19-associated AKI. 11 On the other hand we have to consider the high incidence of acute kidney injury (AKI) during SARS-CoV-2 pneumonia and the possibility of PD as renal replacement therapy in AKI. PD in patients with AKI provides an acceptable form of treatment, in fact recent studies have suggested that outcomes with PD are as good as with extracorporeal RRTs.

Certainly PD could provide some advantages for PD to manage patients with AKI [48] .

A previous study compared PD with continuous renal replacement therapy in critically ill patients with AKI and found that patients in the PD group had lower mortality rate at 28 days, faster recovery of renal function, and less complications of infections [49] .

Furthermore, SARS-CoV-2 is a highly contagious airborne disease. The patients should be kept in an isolation room, should not be transported and should be minimally exposed to healthcare providers. When applying this concept to dialysis for COVID-19 patients, automated PD (APD) is preferred because the cycler can be moved and installed anywhere. Moreover, the PD fluid exchanges occur automatically and only one nurse can manage the cycler. Such minimum contact with the patient reduces not only the risk of contagion, but also the need for personal protective equipment (PPE) use [50] . Lastly, pandemic could determine a different resource allocation in healthcare because of scarce resource settings (clinics/hospitals). PD is simple and efficient, it provides continuous steady fluid removal and requires less equipment when compared with extracorporeal dialysis. Moreover it requires lower work intensity with a nurse being able to manage different PD cyclers simultaneously [51] .

Such an efficient resource management method helps address the shortage of medical equipment and reduce exposure of the healthcare staff, which are critical issues during the pandemic. Because of the above-mentioned benefits, PD should be considered as one of the options to treat COVID-19-related AKI, and APD is the preferred form to minimize the risk of exposure.

The first experience of PD in AKI during SARS-CoV-2 pneumonia was made by Hugh [52]. The second experience was the one of Dr Mihran Naljayan from the Louisiana State University. They have treated with PD 18 patients and reported the following outcomes: died [53] . Clinical experiences and studies support the use of PD in AKI situations; the outcomes are not different from the ones reported with other dialytic techniques such as Continuous Renal Replacement Therapy (CRRT), sustained low-efficiency dialysis and intermittent haemodialysis. A shortage of CRRT and HD machines and supplies, as well as of staff and Personnel Protective Equipments (PPEs), has brought PD to the forefront.

Preliminary experience reported here provides evidence that PD can contribute to reduce the kidney disease contribution on COVID-19 evolution.

Furthermore we have to consider the haemodynamic advantage of PD. Cardiac involvement was also observed in patients with COVID-19. Cardiac injury may result from myocarditis, profound systemic inflammation, or microvascular dysfunction [54] . Thus, renal replacement therapy should be performed with caution The gentle and prolonged removal of body fluids and toxins during PD reduces the risk of hemodynamic instability, which makes PD a treatment of choice for critically ill patients both with AKI or ESRD [49] .

As shown PD have comparable, or even better, outcomes. Frequent, routine trips for dialysis treatments at health care facilities, where individuals with advanced age, a large comorbidity burden, and high rates of hospitalization are cohorted together, fostering a high-risk situation for SARS-CoV-2 transmission. The advantages of PD on reducing infection rate are clear: they didn't reflect only the reduced social contact between patients and health-workers but also clinical aspects. Reports we described confirm that the home based PD limits the risk of SARS-CoV-2 infection. In table 2 we summarize the main experiences about PD as RRT during the pandemic both for ESRD and AKI.

What we learned from the pandemic.

In table 3, we summarize the main messages of our review: current barriers to home dialysis therapies, best practices on the basis of the lessons learnt during the pandemic, long term changes needed to improve use of home dialysis therapies.

The COVID-19 pandemic has highlighted the advantage of receiving home dialysis and in particular PD, thus we can consider the pandemic as an opportunity to re-evaluate and refine existing models of health care delivery at home and overcome barriers to increase the use of home-based dialysis. Beside the high risk of communicable infectious disease, transmission of viral hepatitis and colonization with multidrug-resistant microbes, factors such as poverty, housing instability, care-givers limitations and lack of storage space 13 present real challenges to home dialysis use, and there may also represent an around patients' capacity for learning PD. Some of these factors may be overcome by proactively providing assistance. Initiating PD is far more time intensive than HD. It requires more extensive discussions with patients and their caregivers; identifying and collaborating with other specialists and primary care providers, empowering patients and their families to take a leadership role in their own care. Previous study have shown the association between appropriate education and proportion of patients who choose PD [55] . With this in mind biggest efforts should be conducted to increase proportion of patients who choose PD. For example in UK and Canada, assistance is available for older people to have PD in their home or nursing homes. Previously studies have demonstrated an high satisfaction in patients with assisted -PD [56] .

These efforts include providing patients adeguate education about PD, exploring models of providing assistance, developing robust telemedicine strategies that minimize in-persone interactions. During the pandemic the key-role of tele-health has emerged. Infact telemedicine allows to maintain the social isolation of many patients, encouraging at-risk group professionals to work from home, preserving the health of many who are at the forefront by decreasing the flow of people in the clinic environment.

Another major factor to be aware of is that in general among most countries, PD is more cost-effective than hemodialysis. The United States Renal Data System 2012 Annual Report (USRDS) reports an annual cost of hemodialysis per patient around US $87 500

per year, while that of PD is around US $ 66 750 [57] . So increasing the use of PD in the US produce an important saving to the health care system over years. These advantages go beyond the emergency-state imposed by pandemic but offer opportunity that can be considered over the time to increase the number of patients receiving PD.

None declared. Limiting need to travel is an advantage in the "lockdown" Table 3 . Lessons from pandemic and considerations regarding home dialysis treatments.

Mitigating Risk of COVID-19 in Dialysis Facilities CJASN

COVID-NET Surveillance Team. Risk Factors for COVID-19-associated hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System Clin Infect Dis

Aspects of Immune Dysfunction in End-stage Renal Disease

Betjes Immune cell dysfunction and inflammation in end-stage renal disease

Anteo Di Napoli, et al on behalf of the Italian Society of Nephrology COVID-19 Research Group Exposure to novel coronavirus in patients on renal replacement therapy during the exponential phase of COVID -19 pandemic: survey of the Italian Society of

US Renal Data System 2019 Annual Data Report: epidemiology of kidney disease in the United States

Rajnish Mehrotra and Marcello Tonelli The current and future landscape of dialysis

Talat Alp Ikizler, Claudio Ronco The COVID-19 infection in dialysis: are home-based renal replacement therapies a way to improve patient management

Rachael L Morton Home hemodialysis: a comprehensive review of patient-centered and economic considerations ClinicoEconomics and Outcomes Research

Home haemodialysis

Blagg Home haemodialysisinternational trends and variation

Home hemodialysis treatment and outcomes: retrospective analysis of the Knowledge to Improve Home Dialysis Network in Europe (KIHDNEy) cohort

USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases

Outcomes of extended-hours hemodialysis performed predominantly at home

Extended-hours hemodialysis is associated with lower mortality risk in patients with end-stage renal disease

Long interdialytic interval and mortality among patients receiving hemodialysis

Frequent hemodialysis schedules are associated with reduced levels of dialysis induced cardiac injury

The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial

Intensified home hemodialysis: clinical benefits, risks and target populations

Nocturnal haemodialysis: an Australian cost comparison with conventional satellite haemodialysis

An operating cost comparison between conventional and home quotidian hemodialysis

Chan The Rise, Fall, and Resurgence of Home Hemodialysis Seminars in Dialysis

Determinants of modality selection among incident US dialysis patients: Results from a national study

Predicting a patient's choice of dialysis modality: Experience in a United Kingdom renal department

Patient education and access of ESRD patients to renal replacement therapies beyond in-center hemodialysis

Effect of an in-hospital chronic kidney disease education program among patients with unplanned urgent

Implementing Hemodialysis in the Home: A Practical Manual First Edition Copyright ©

Rajnish Mehrotra Advancing American Kidney Health An introduction CJASN

Home Dialysis in the Coronavirus Disease2019 Era Adv Chronic Kidney Dis

Rajnish Mehrotra and Marcello Tonelli The current and future landscape of dialysis

Insights into nephrologist training,clinical practice, and dialysis choice

Kalloo Early Use of Telehealth in Home Dialysis during the COVID-19 Pandemic

& on behalf of the European Kidney Health Allianceet al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action

Cost Controversies of a "Home Dialysis First

Financial Support for Home Dialysis Patients in Australia -Kidney health Australia-The home network

A Systematic Approach To Promoting Home Hemodialysis during End Stage Kidney Disease

Qiang Yao Immune dysfunction in dialysis patients--prevention and treatment strategies

Impact of Dialysis Modality on the Incidence of 2009 Pandemic H1N1 Influenza in End-Stage Renal Disease Patients

Strategies regarding COVID-19 in PD patients Adapted from Peking University First Hospital

UK Renal Registry: Weekly COVID-19 Surveillance

COVID-19 in Peritoneal Dialysis Patients

Remote patient management of peritoneal dialysis during COVID-19 pandemic

Peritoneal dialysis in the time of coronavirus disease 2019

Use of peritoneal dialysis in AKI: a systematic review

Effect of peritoneal dialysis on respiratory mechanics in acute kidney injury patients

Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury

Minimizing the risk of COVID-19 among patients on dialysis

Use of PD for COVID-19-Associated AKI: Clinical Experience and Updated 2020 ISPD Guidelines

Cardiac involvement in a patientwith coronavirus disease 2019 (COVID-19)

COVID-19 and the cardiovascular system

Patient education and peritoneal dialysis modality selection: A systematic review and meta-analysis

Quality of life and physical function in older patients on dialysis: A comparison of assisted peritoneal dialysis with hemodialysis

Cost of peritoneal dialysis and haemodialysis across the world

R2-fig1 RRT modalities by country